Last updated: February 20, 2026
What companies manufacture or supply ozanimod hydrochloride?
Multiple companies produce or distribute ozanimod hydrochloride, a selective sphingosine-1-phosphate receptor modulator approved by the U.S. Food and Drug Administration (FDA) for multiple sclerosis (MS) and ulcerative colitis. These suppliers range from pharmaceutical manufacturers to intermediaries involved in the supply chain.
Key Pharmaceutical Manufacturers
Exact source identification for the active pharmaceutical ingredient (API):
Ozanimod hydrochloride API is primarily manufactured by the originator pharmaceutical company, Celgene Corporation, which was acquired by Bristol-Myers Squibb (BMS) in 2019.
Bristol-Myers Squibb (BMS):
- BMS is the sole developer and marketer of Ozanimod (brand name Zeposia).
- BMS produces the API domestically for global distribution.
- BMS's manufacturing facilities are certified under Good Manufacturing Practice (GMP) standards.
API Suppliers and Contract Manufacturers
While BMS is the main supplier, some contract manufacturing organizations (CMOs) and intermediaries provide ozanimod hydrochloride API for development or generic formulations, including:
- Catalent: A major CMO involved in early-stage development and API supply for certain projects.
- Fujifilm Diosynth Biotechnologies: Provides contract manufacturing services, but publicly available data on ozanimod-specific API production is limited.
- Mitsubishi Chemical Corporation: Reported involvement in API synthesis for some S1P receptor modulators; no confirmation for ozanimod hydrochloride specifically.
Distribution Channels
Pharmaceutical distributors:
- McKesson, AmerisourceBergen, and Cardinal Health stock Zeposia for pharmacies and hospitals, but do not supply the API directly to end-users outside BMS's distribution.
- API wholesalers: Limited publicly available data on wholesale API suppliers.
Generic vendors:
- As of the current date, no generic formulations have been approved, limiting independent API sourcing to BMS and its authorized partners.
Supply Chain Considerations
- GMP Certification: BMS’s API factories hold certifications from authorities such as the FDA, EMA, and other regulators.
- Geographical sourcing: The primary manufacturing facilities are located in the U.S. and Europe to meet regional demands.
Summary Table
| Entity |
Role |
Certification & Notes |
| Bristol-Myers Squibb |
Original API manufacturer |
GMP-certified, exclusive rights in many markets |
| Catalent |
Contract manufacturing / API supply |
GMP-certified, supports clinical and commercial supplies |
| McKesson / AmerisourceBergen |
Distributors of finished drug product |
Do not supply API, only finished product |
| Fujifilm Diosynth |
Contract services (uncertain) |
No specific confirmation for ozanimod API |
What are the implications for market competition?
- BMS controls API production for ozanimod hydrochloride, limiting the market to licensed producers.
- No active public authorization for biosimilars or generics, restricting price competition.
- New entrants would need GMP-compliant manufacturing capability and regulatory approval.
Key Takeaways
- Bristol-Myers Squibb is the primary supplier and manufacturer of the ozanimod hydrochloride API.
- Contract manufacturing organizations support BMS's API supply, but no commercial-scale generic suppliers exist currently.
- Distribution is handled through authorized pharmaceutical supply channels.
- The supply chain is tightly controlled, with no open markets for independent API sourcing.
FAQs
1. Are there any approved generic versions of ozanimod hydrochloride?
No. As of March 2023, no generic formulations have received approval from major regulatory agencies (FDA, EMA).
2. Can other companies produce ozanimod hydrochloride API?
Production requires GMP certification and regulatory approval, which restricts manufacturing rights primarily to BMS or its licensed partners.
3. Who supplies ozanimod hydrochloride for clinical trials?
BMS or contracted CMOs provide API for clinical studies under confidentiality agreements.
4. Is it possible to buy ozanimod hydrochloride API directly?
No. API purchasing is restricted to licensed pharmaceutical entities with GMP compliance.
5. Might new suppliers enter the market?
Potentially, if patent rights are expiring and regulatory pathways open for biosimilars or generics, but no confirmed plans are publicly announced.
References
- Bristol-Myers Squibb. (2022). Zeposia (ozanimod) prescribing information.
- U.S. Food and Drug Administration. (2020). FDA approves Bristol-Myers Squibb’s Zeposia for relapsing forms of multiple sclerosis.
- European Medicines Agency. (2022). EMA assessment report on ozanimod.
- IQVIA. (2023). Global pharmaceutical supply chain report.
